In clinical practice, a dose‐dense TMZ regimen is applied to some recurrent MGMT‐unmethylated gliomas,15 based on the idea that a high dose of TMZ would probably deplete MGMT in tumor cells via suicide inhibition.16 However, these large clinical trials failed to produce an OS benefit of increasing TMZ dose intensity.17, 18 Another limitation of this strategy is that high‐dose drug exposure inevitably leads to increased side effects.15, 18. The gene discussed is MGMT; the disease is neoplasm.